Vistin Pharma ASA reported record full year (FY) 2025 results, with revenue reaching NOK 452 million, marking an all-time high for the company and reflecting a 12% increase in sales volume for the year. Fourth quarter (Q4) 2025 revenue stood at NOK 111 million. FY 2025 EBITDA was NOK 115 million, representing a 10% rise. Q4 EBITDA reached NOK 26 million. Earnings per share for 2025 were NOK 1.69, an increase of 19%. The company maintained a strong balance sheet with an equity ratio of 75% and a net cash position of NOK 16 million at year-end. Based on the preliminary 2025 results, the Board of Directors will propose an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November. Management attributed the record results to strong commercial execution and highlighted continued growth in both top- and bottom-line figures. The company also noted that record high sales volumes were partially offset by lower global metformin prices and product mix effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vistin Pharma ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164244-en) on February 12, 2026, and is solely responsible for the information contained therein.